Join CAMP4 Therapeutics for a virtual Analyst Day featuring presentations and Q&A led by CAMP4’s executive leadership team, with participation from patient advocates and a leading KOL.

Discussions will focus on CMP-002, a potential first-in-class disease-modifying therapeutic for SYNGAP1-related disorder, including clinical trial design for the company’s FIH Phase 1/2 clinical trial expected to initiate in Q4 2026.

Stéphane Auvin, MD, PhD (Robert Debré University Hospital, Université Paris Cité) will join to discuss the unmet need and current treatment landscape for SYNGAP1-related disorder.

A live question and answer session will follow the formal presentations.